MLTX

MoonLake Immunotherapeutics

Healthcare
Biotechnology
$1.05B market cap

Forecast run · Sep 14, 2026Upside rank 86 of 3,136

Model Signal

ForecastQ Daily Probabilities

75.5%

28.7%

51.2%

Analyst Consensus

Recommendation2.32/5 Buy

Last price$12.51

Price target$50.00

Implied move+299.7%

Analysts19

ForecastQ Portfolios

MLTX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.